A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer (Panc001)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by AHS Cancer Control Alberta
Sponsor:
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT01586611
First received: April 24, 2012
Last updated: October 1, 2014
Last verified: October 2014
  Purpose

Chemotherapy is often used to help shrink the cancer temporarily and may improve survival for patients with incurable pancreas cancer that has spread to other organs. In Canada, the gemcitabine chemotherapy is used to treat pancreas cancer that has spread. The combination of oxaliplatin with other chemotherapies, including 5-fluorouracil, leucovorin, and irinotecan has also been studied and has benefit for patients with advanced pancreas cancer. To date, there is no test that can be done on a patient's tumour to tell if chemotherapy will work in pancreatic cancer. Human equilibrative nucleoside transporter 1 (hENT1) has been shown to be a possible predictor that gemcitabine may or may not work but this needs to be proven in a randomized study where patients get treated with gemcitabine or a different kind of chemotherapy while their tumours get tested for hENT1.

This study is being done because we want to prove that hENT1 can predict if gemcitabine will work in advanced pancreas cancer and if it can, we also would like to show that a different chemotherapy combination called FOLFOX (a combination of 5-fluorouracil, leucovorin, and oxaliplatin) will be helpful for patients whose tumours don't have hENT1.


Condition Intervention Phase
Metastatic Pancreas Cancer
Drug: 5FU, leucovorin, oxaliplatin
Drug: Gemcitabine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicentre, Randomized, Open Label, Phase III Study of Gemcitabine Versus FOLFOX in the First Line Setting for Metastatic Pancreatic Cancer Patients Using Human Equilibrative Nucleoside Transporter 1 (hENT1) Biomarker Testing.

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Primary Outcome Measures:
  • The difference Progression Free Survival (PFS) between Gemcitabine and FOLFOX treated patients in hENT1 high and hENT1 low pancreatic adenocarcinoma. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
    Progression free survival will be measured from the date of diagnosis to the date of progression or death, patients who did not progress or is alive at the last date of follow-up will be censored for the analysis. Kaplan-Meier method will be used to estimate the survival function and log-rank test will be utilized to compare the study arms. The median PFS and the corresponding 95% confidence interval will be used for reporting purpose. The hazard ratio and the corresponding 95% two-sided confidence interval using Cox-proportional hazard regression will be presented.


Secondary Outcome Measures:
  • The difference in overall response rate (ORR) between the two treatment arms. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • The rate of disease control (DCR), defined as the sum of complete response rate (RR), partial RR, and stable disease between the two treatment arms. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
  • The difference in overall survival (OS) between the two treatment arms. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
  • Health-related quality of life (HRQL) parameters in patients with metastatic pancreas adenocarcinoma treated in both treatment arms. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]

Estimated Enrollment: 175
Study Start Date: June 2012
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Gemcitabine
Cycles to be 4 weeks in length Gemcitabine 1000 mg/m2 IV weekly for 3 weeks then one week off
Drug: Gemcitabine
1000 mg/m2 IV weekly for 3 weeks then one week off
Experimental: FOLFOX
Cycles to be 2 weeks in length Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
Drug: 5FU, leucovorin, oxaliplatin
Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically documented metastatic pancreatic adenocarcinoma not previously treated with palliative systemic therapy
  • Metastatic disease based on the presence of clinically and/or radiologically documents Measurable disease base on RECIST.
  • Adequate tissue (core biopsy) available for IHC testing of hENT1. This may be from primary tumour or metastatic site. Fine needle aspiration biopsies will not be allowed. Histological/cytological confirmation of tissue to ensure sufficient material is available for hENT1 analysis by the Cross Cancer Institute is required prior to starting a patient on study. Biopsies from metastatic sites must be obtained ≥ 3 months after any adjuvant chemotherapy (if applicable). If a patient has had previous surgical resection of their primary tumours, that tissue can be utilized. Tissue sufficient for preparing ≥ 10 unstained slides for central storage and testing is required.
  • ECOG performance status of 0 - 1.
  • Age ≥ 18 years.
  • Life expectancy of at least 3 months based on discretion of treating oncologist.
  • Adequate hematologic function defined by the following laboratory parameters:
  • Hemoglobin ≥ 100
  • Platelet count ≥ 100
  • Absolute granulocyte count ≥ 1.5
  • Adequate hepatic and renal function defined by the following laboratory parameters:
  • AST and ALT ≤ 2.5 X upper limit of institutional normal (≤ 5 if liver metastases)
  • bilirubin ≤ upper limit of institutional normal
  • calculated creatinine clearance of ≥ 50 mL/min using the Cockcroft-Gault formula, if just below 50 mL/min based on this formula then GFR ≥ 50 mL/min as determined by 24 hr urine collection
  • Patients who have received prior chemotherapy or radiation delivered as part of initial curative therapy (i.e. neoadjuvant or adjuvant chemotherapy administered alone and/or concurrently delivered with radiation and/or surgery) are permitted as long as that treatment was completed at least 6 months prior to study start date.
  • Patients may have received prior palliative radiotherapy (unless radiation was curative therapy to pelvis or to ≥ 25% of bone marrow stores) if this radiation was ≥ 4 weeks before study entry and patients must have recovered from the toxic effects of this treatment
  • Patients may have received prior surgery if this surgery was ≥ 4 weeks before study entry and patients must have recovered from the toxic effects of this treatment.
  • Patients must have the ability to read, understand, and sign an informed consent and must be willing to comply with study treatment and follow-up.

Exclusion Criteria:

  • Patients who have received prior palliative chemotherapy for their metastatic pancreatic adenocarcinoma.
  • Radical pancreatic resections (e.g. Whipple procedure) are not allowed < 6 months prior to randomization. Exploratory laparotomy, palliative (e.g. bypass) surgery, or other procedures (e.g. stents) are not allowed < 14 days prior to randomization. In any of the above cases, patients must be adequately recovered and stable prior to randomization.
  • Prior treatment with > 6 cycles of traditional alkylating agent-based chemotherapy, > 2 cycles of carboplatin-based chemotherapy, prior treatment with irinotecan or oxaliplatin chemotherapy, or concurrent treatment with other experimental drugs or anti-cancer therapy.
  • Curative radiation treatment to the pelvis or radiation therapy to ≥ 25% of bone marrow stores.
  • Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, short gut syndrome, or history of bowel obstruction due to peritoneal metastases.
  • Previous or concurrent malignancies, excluding curatively treated in situ carcinoma of the cervix or non-melanoma skin cancer, unless at least 5 years have elapsed since last treatment and the patient is considered cured.
  • Any serious medical condition within 6 months prior to study entry such as myocardial infarction, uncontrolled congestive heart failure, unstable angina, active cardiomyopathy, unstable ventricular arrhythmia, cerebrovascular diseases, uncontrolled hypertension, uncontrolled diabetes, uncontrolled psychiatric disorder, serious infection, active peptic ulcer disease, or other medical condition that may be aggravated by treatment.
  • Known dihydropyrimidine dehydrogenase (DPD) deficiency.
  • Pre-existing neuropathy ≥ grade 2 from any cause.
  • Patients with unstable metastasis to the central nervous system are excluded. Patients who have treated brain metastasis and are off steroids, anticonvulsants, and have documented stability of lesions for at least 3 months may be eligible. A CT scan or MRI is NOT required to rule out brain metastases unless there is clinical suspicion of CNS involvement.
  • Pregnant or lactating women; women of child bearing potential must have a negative serum pregnancy test within 7 days of trial registration. Women or men of child bearing potential must use effective contraception (defined by the treating physician) which must be documented in study CRFs.
  • Any other reason the investigator considers the patient should not participate in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01586611

Contacts
Contact: Neil S Chua, MD, FRCPC 780-432-8340 neil.chua@albertahealthservices.ca

Locations
Canada, Alberta
Cross Cancer Institute Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Jennifer L Spratlin, MD FRCPC    780-432-8514    Jennifer.Spratlin@albertahealthservices.ca   
Contact: Karen Mulder, MC FRCPC    780-432-8514    Karen.Mulder@albertahealthservices.ca   
Sub-Investigator: Jennifer L Spratlin, MD FRCPC         
Sub-Investigator: Karen Mulder, MD FRCPC         
Principal Investigator: Karen King, MC FRCPC         
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Principal Investigator: Neil S. Chua, MD, FRCPC Cross Cancer Institute
  More Information

No publications provided

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT01586611     History of Changes
Other Study ID Numbers: Panc001
Study First Received: April 24, 2012
Last Updated: October 1, 2014
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Gemcitabine
Oxaliplatin
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Radiation-Sensitizing Agents

ClinicalTrials.gov processed this record on October 19, 2014